Yashoda Medicity Gains DGME Approval to Establish Brain Stem Death Certification Committee

Yashoda Medicity has received approval from the Directorate General of Medical Education (DGME) to constitute a brain stem death certification committee, a regulatory prerequisite that directly enables the hospital to initiate deceased donor organ procurement under India's transplantation framework.

The newly constituted committee is mandated to conduct timely brain stem death certification, a step that sits at the procedural and legal gateway to any deceased donor transplant program. Without a DGME-approved panel in place, hospitals cannot legally certify brain stem death or proceed with organ retrieval, regardless of clinical readiness. The approval therefore removes a structural compliance barrier that has historically constrained deceased donor activity at facility level.

For hospital administrators and clinical governance leads, the operational read is direct: the committee's formation aligns Yashoda Medicity with the requirements under the Transplantation of Human Organs and Tissues Act (THOTA) and its associated rules, which govern committee composition, documentation, and certification timelines. Regulatory inspections of transplant programs routinely scrutinize committee constitution records, certification logs, and the interval between clinical determination and formal declaration.

The approval also carries a supply-side implication for the broader organ allocation ecosystem. Certified brain stem death cases feed directly into the regional and national organ sharing networks coordinated through NOTTO and state-level bodies. Expanding the number of DGME-approved certification committees at tertiary hospitals increases the potential pool of retrievable organs, which remains the primary bottleneck in India's deceased donor transplant rate relative to demand.

Yashoda Medicity's committee activation will be measured against certification turnaround times and the conversion rate from certified cases to completed retrievals, both of which are tracked by transplant coordinators and state authorities as indicators of program maturity.

Source: Media4Growth via Indian Pharma Post, 8 June 2026.